论文部分内容阅读
目的:研究iv gtt奈替米星在新生儿体内的稳态药物动力学,观察疗效和安全性.方法:7例新生儿患者按7mg/kg.qd,iv gtt奈替米星,用药3d后用荧光偏振免疫法测定血药浓度,同时对奈替米星的抗感染效果及不良反应进行观察.结果:新生儿iv gtt奈替米星后,呈二房室动力学模型,主要药动学参数:C_(max)(18.38±5.43)μg/ml,T_(1/2β)(5.21±1.14)h.Vc(0.34±0.10)L/kg,CL(0.25±0.05)L/h,AUC(81.67±16.00)[(mg/L)·h]用药7d临床疗效满意并未发现不良反应.结论:肾功能正常的新生儿奈替米星qd iv gtt可获得较好的疗效并具有良好的安全性.
Objective: To study the steady-state pharmacokinetics of netilmicin iv in neonates, and to observe the efficacy and safety.Methods: 7 neonates were treated with 7 mg / kg.qd iv netilmicin after 3 days Fluorescence polarization immunoassay was used to determine the concentration of plasma and the anti-infective effect and adverse reaction of netilmicin were observed.Results: Neonatal iv netilmicin showed a two-compartment dynamic model with the main pharmacokinetic parameters : Cmax 18.38 ± 5.43 μg / ml, T 1/2 1/2 5.21 ± 1.14 h.Vc 0.34 ± 0.10 L / kg, CL 0.25 0.25 L / h, AUC 81.67 ± 16.00) [(mg / L) · h] The clinical efficacy was satisfactory and no adverse reactions were found on the 7th day after treatment.CONCLUSIONS: Netilmicin qtt iv gtt with normal renal function can obtain good curative effect and good safety .